Serodiagnosis of Borreliosis: Indirect Immunofluorescence Assay, Enzyme-Linked Immunosorbent Assay and Immunoblotting

Wojciechowska‐Koszko, Iwona; Maczynska, Iwona; Szych, Zbigniew; Giedrys-Kalemba, Stefania

doi:10.1007/s00005-010-0111-0

Cited by 9 publications

(16 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ELISA serologic method is recommended as a screening test in epidemiological studies (15). Reagent antigens used in the ELISA kit cannot be standardized so discrepancy may be found between the results obtained in the study.…”

Section: Discussionmentioning

confidence: 99%

“…In our study, ELISA and WB kits used the antigen of the European strain. Studies indicate that if the immunoblotting assay includes OspC antigens to detect IgM and vlsE antigen to detect IgG, the specificity of the diagnostic test is increased (15,17). In our study, in the WB test, the number of OspC antigen bands (other bands: p39, vlsE) in IgMpositive patients and the number of vlsE antigen bands in IgG-positive patients was seen to be more positive (other bands: OspC, p39, p83, p58, p21, p20, p19, and p18).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Borrelia burgdorferi sensu lato seroprevalencein the province of Bolu, Turkey*

Bucak¹,

Koçoğlu²,

Taş³

et al. 2016

Turk J Med Sci

View full text Add to dashboard Cite

disease is a multisystemic disease caused by Borrelia species, and it is transmitted to humans by ticks of the species Ixodes. There are three genotypes of the Lyme disease agent: Borrelia burgdorferi sensu stricto, Borrelia garinii, and Borrelia afzelii. They are grouped together under the name B. burgdorferi sensu lato (1). The causative agent of Lyme disease, B. burgdorferi, was isolated in 1982 (2). Lyme disease is evident in three stages. The first stage includes erythema migrans (EM) and needs no serological testing. Diagnosis becomes more difficult in the second and third stages. In such cases, two-step diagnosis is necessary. The first step is based on an enzymelinked immunosorbent assay (ELISA) test, and positive results should be confirmed by Western blot (WB) (3). Cross-reactions have been found between antibodies to syphilis, leptospirosis, relapsing fever, varicella, infectious mononucleosis, and some autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis), and ELISA tests may provide false positive results so the results should be confirmed by WB (4). This disease is a common tick-borne zoonosis in European countries and the United States. In Turkey, the first cases were reported in 1990 in the Black Sea and Aegean regions (1). Because Lyme disease is not a compulsory notification disease in Turkey and due to confusion with clinical signs of other diseases, the exact prevalence is not known.In the present study, the aim was to determine the seroprevalence of Borrelia burgdorferi sensu lato in the city center and the province of Bolu, Turkey.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Evaluation of Borrelia burgdorferi sensu lato seroprevalencein the province of Bolu, Turkey*

Bucak¹,

Koçoğlu²,

Taş³

et al. 2016

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

“…The recommended two-tiered testing also misses as much as 44% of those with late Lyme disease. 24 Part of the difficulty in finding antibodies against Borrelia is that they can be bound in circulating immune complexes. These tests also do not detect other related Borrelia species that cause Lyme-like illness, such as Borrelia miyamotoi and Borrelia sensu lato .…”

Section: Background and Overviewmentioning

confidence: 99%

Empirical validation of the Horowitz Multiple Systemic Infectious Disease Syndrome Questionnaire for suspected Lyme disease

Citera¹,

Freeman²,

Horowitz³

2017

IJGM

View full text Add to dashboard Cite

PurposeLyme disease is spreading worldwide, with multiple Borrelia species causing a broad range of clinical symptoms that mimic other illnesses. A validated Lyme disease screening questionnaire would be clinically useful for both providers and patients. Three studies evaluated such a screening tool, namely the Horowitz Multiple Systemic Infectious Disease Syndrome (MSIDS) Questionnaire. The purpose was to see if the questionnaire could accurately distinguish between Lyme patients and healthy individuals.MethodsStudy 1 examined the construct validity of the scale examining its factor structure and reliability of the questionnaire among 537 individuals being treated for Lyme disease. Study 2 involved an online sample of 999 participants, who self-identified as either healthy (N=217) or suffering from Lyme now (N=782) who completed the Horowitz MSIDS Questionnaire (HMQ) along with an outdoor activity survey. We examined convergent validity among components of the scale and evaluated discriminant validity with the Big Five personality characteristics. The third study compared a sample of 236 patients with confirmed Lyme disease with an online sample of 568 healthy individuals.ResultsFactor analysis results identified six underlying latent dimensions; four of these overlapped with critical symptoms identified by Horowitz – neuropathy, cognitive dysfunction, musculoskeletal pain, and fatigue. The HMQ showed acceptable levels of internal reliability using Cronbach’s coefficient alpha and exhibited evidence of convergent and divergent validity. Components of the HMQ correlated more highly with each other than with unrelated traits.DiscussionThe results consistently demonstrated that the HMQ accurately differentiated those with Lyme disease from healthy individuals. Three migratory pain survey items (persistent muscular pain, arthritic pain, and nerve pain/paresthesias) robustly identified individuals with verified Lyme disease. The results support the use of the HMQ as a valid, efficient, and low-cost screening tool for medical practitioners to decide if additional testing is warranted to distinguish between Lyme disease and other illnesses.

show abstract

“…In patients with early phase LD, the most commonly detected antibodies are IgM against flagelin protein (p41) and outer surface protein C (OspC). Many studies have also been confirmed in Poland (4,15,16).…”

Section: S70mentioning

confidence: 79%

Seroprevalence of Lyme disease in Eastern Slovakia

Bušová¹,

Dorko²,

Rimárová³

et al. 2018

Cent Eur J Public Health

View full text Add to dashboard Cite

Objective: Lyme disease (LD) is chronic, multi-system zoonosis transmitted by ticks, and LD aetiological agents are spirochetes of the Borrelia burgdorferi sensu lato complex. The aim of the cross-sectional study was to analyze the LD incidence on the basis of the presence of specific antibodies in the serum of patients in Eastern Slovakia, and to compare the results of serological ELISA and immunoblot assays. Methods: Venous blood with questionnaires was obtained by field sampling of respondents from Eastern Slovakia. Overall, we examined 537 human sera by the ELISA and for confirmation we tested all positive IgG antibodies against the Borrelia immunoblot assay. Results: Our results confirmed the high serum prevalence of anti-Borrelia antibodies (17.9% for IgG), while the immunoblot seropositive test was confirmed in 69.8% of responders from ELISA IgG positive sera. Positive antibodies of the IgM class were found in 7.6% of the population under study. Most commonly found were antibodies against VlsE (80.2%), p41 (66.7%), p18 (56.3%), p100 (41.7%), p58 (31.3%), and p39 (30.2%). Conclusion: It should be noted that detection of antibodies against B. burgdorferi s.l. is only an indirect evidence of the presence of this bacterium in the development of clinical signs of LD in humans. Laboratory LD tests should be performed in accordance with valid standards, positive and uncertain results must be confirmed by the Western Blot/Immunoblot assay.

show abstract

Serodiagnosis of Borreliosis: Indirect Immunofluorescence Assay, Enzyme-Linked Immunosorbent Assay and Immunoblotting

Cited by 9 publications

References 11 publications

Evaluation of Borrelia burgdorferi sensu lato seroprevalencein the province of Bolu, Turkey*

Evaluation of Borrelia burgdorferi sensu lato seroprevalencein the province of Bolu, Turkey*

Empirical validation of the Horowitz Multiple Systemic Infectious Disease Syndrome Questionnaire for suspected Lyme disease

Seroprevalence of Lyme disease in Eastern Slovakia

Contact Info

Product

Resources

About